Table 3 DOR, sensitivity, specificity and likelihood ratios with calculated 95% confidence intervals for each study in patients sub-grouped by INSS stage.
Study | DOR (95% CI) | Sens (95% CI) | Spec (95% CI) | PLR (95% CI) | NLR (95% CI) |
|---|---|---|---|---|---|
INSS stage 3 | |||||
Combaret et al.13 | 51.0 (1.70–1525.8) | 0.80 (0.38–0.96) | 1.00 (0.68–1.00) | 13.5 (0.9–207.6) | 0.265 (0.066–1.068) |
Gotoh et al.14 | 75.0 (1.16–4868.6) | 1.00 (0.34–1.00) | 1.00 (0.65–1.00) | 13.3 (0.9–204.7) | 0.178 (0.014–2.247) |
Combaret et al.12 | 91.0 (3.05–2718.1) | 0.75 (0.30–0.95) | 1.00 (0.83–1.00) | 28.0 (1.7–458.8) | 0.308 (0.081–1.176) |
Combaret et al.15 | 152.8 (7.60–3060.2) | 0.75 (0.51–0.90) | 1.00 (0.88–1.00) | 41.2 (2.6–651.7) | 0.270 (0.122–0.596) |
Kojima et al.16 | 75.0 (1.16–4868.6) | 1.00 (0.34–1.00) | 1.00 (0.65–1.00) | 13.3 (0.9–204.7) | 0.178 (0.014–2.247) |
Yagyu et al.17 | 66.0 (5.20–833.6) | 0.92 (0.65–0.99) | 0.86 (0.60–0.96) | 6.4 (1.8–23.4) | 0.097 (0.015–0.643) |
Ma et al.18 | 81.0 (1.14–5778.7) | 1.00 (0.21–1.00) | 1.00 (0.77–1.00) | 21.0 (1.2–358.4) | 0.259 (0.023–2.865) |
INSS stage 4 | |||||
Combaret et al.13 | 1105.0 (43.2–28280.7) | 1.00 (0.87–1.00) | 0.97 (0.85–0.99) | 22.2 (4.6–106.4) | 0.020 (0.001–0.313) |
Gotoh et al.14 | 999.0 (18.63–53582.1) | 1.00 (0.77–1.00) | 1.00 (0.82–1.00) | 36.6 (2.4–565.8) | 0.037 (0.002–0.558) |
Combaret et al.12 | 85.0 (6.81–1061.0) | 0.91 (0.62–0.98) | 0.89 (0.69–0.97) | 8.6 (2.3–32.5) | 0.102 (0.016–0.663) |
Combaret et al.15 | 912.08 (50.0–16628.0) | 0.85 (0.72–0.93) | 1.00 (0.96–1.00) | 142.0 (8.9–2258.4) | 0.156 (0.077–0.316) |
Kojima et al.16 | 377.0 (6.7–21160.0) | 1.00 (0.78–1.00) | 1.00 (0.61–1.00) | 13.5 (0.9–195.9) | 0.036 (0.002–0.552) |
Yagyu et al.17 | 211.2 (23.4–1908.8) | 0.87 (0.73–0.94) | 0.97 (0.85–0.99) | 28.7 (4.1–198.2) | 0.136 (0.060–0.308) |
Ma et al.18 | 188.0 (15.2–2324.4) | 0.89 (0.57–0.98) | 0.96 (0.86–0.99) | 21.8 (5.5–86.3) | 0.116 (0.018–0.736) |
